Cipla Ltd. — Capital/Financing Update 2022

Aug 30, 2022

Cipla

30[th ] August 2022

(1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th ] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA EQ

Scrip Code: 500087

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph 11, L-1840 Luxembourg

Sub: Intimation under Regulation 30 read with Schedule Ill of SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") and further to the intimation dated 15[th ] July 2019, we hereby notify that Cipla (EU) Limited, ("Cipla EU"), wholly owned subsidiary of the Company in UK has agreed to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical Co. Ltd., a subsidiary of Cipla EU in China. Post-acquisition, Cipla EU's stake in the subsidiary, will increase to 93.10%.

Requisite details under SEBI Listing Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9[th ] September 2015 are enclosed as Annexure - I to this letter.

Please take the above information on record.

Thankyou

Yours faithfully,

For Cipla Limited

==> picture [76 x 29] intentionally omitted <==

Rajendra Chopra Company Secretary

Prepared by: Simona Dsouza

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Pa rel, Mumbai-400 013, India P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Sr.No.	Particulars	Details
a)	Nameofthetargetentity,details inbriefsuchassize,turnoveretc.;	Nameofthetargetentity:Cipla(Jiangsu)PharmaceuticalCo.Ltd.("JVCo.")**Brief Details:**TheJVCo.isajointventurebetweenCipla(EU)Limited and Jiangsu XiDi PharmaceuticalsCo.,Ltd(formerlyknownasJiangsuAcebrightPharmaceuticals Co., Ltd),incorporatedin 2019, inChina,forthepurposeofmanufacturing,selling anddistributionofpharmaceutical products, research anddevelopmentservices and analyticaldevelopmentservices.**Turnover:**Nilason3l51March2022 sincetheJVCo.isyettocommenceitsoperations
b)	Whethertheacquisitionwouldfallwithinrelatedpartytransaction(s) andwhetherthepromoter/promotergroup/groupcompanieshave anyinterestintheentitybeing acquired?Ifyes,natureofinterestand detailsthereofandwhetherthesameisdoneat"arm'slength";	The proposed acquisitionisnota relatedpartytransactionundertheCompanies Act, 2013orINDAS24.ForthelimitedpurposeofListing Regulations,thetransactionisa relatedpartytransactionandwillbeatarm's length.Noneofthepromoter/promotergroup/groupcompanies have anyinterestintheentity.
c)	Industrytowhichtheentitybeingacquired belongs;	PharmaceuticalIndustry
d)	Objectsandeffectsofacquisition(includingbutnotlimitedto,disclosureofreasonsforacquisitionoftargetentity,ifits businessisoutsidethemainlineofbusinessofthelistedentity);	Toprovidequalitydrugs andstrengthenpresence inChina.
e)	Briefdetailsofanygovernmentalorregulatoryapprovalsrequiredfortheacquisition;	The acquisitionofadditionalstakewillbe subjectto(i)compliancewithapplicable laws and (ii) approvalsfromregulatoryauthoritiesin China.
f)	Indicativetime-periodforcompletionoftheacquisition;

		Cip
g)	Natureofconsideration - whethercashconsiderationorshare swap and detailsofthesame;	Conversionofexisting shareholder's loanintocapital.
h)	Costofacquisitionorthepriceatwhichtheshares are acquired	USO16.40million.
i)	Percentageofshareholding /controlacquired and /ornumberofsharesacquired;	Uponcompletionofacquisitionofadditionalstake,CiplaEUwillhold93.10% stake intheJVCo.
j)	Brief backgroundabouttheentityacquired intermsofproducts/lineofbusinessacquired,dateofincorporation,historyoflast 3 years'turnover,countryinwhichtheacquiredentityhas presence and anyothersignificantinformation(inbrief)	**Brief background:**Pleaserefer(a) above**DateofIncorporation:**8thAugust 2019**Historyoflast 3 years turnover:**Nil sincetheJVCo.isyettocommenceits operations.**Country:**China